by swisschambei in Engineering / Manufacturing
Swiss pharmaceutical giant Novartis is expanding its research and development of innovative drugs in China, an executive of the company said. Novartis is expected to submit 50 new drug applications for regulatory approval in China between 2019 and 2023, John Tsai, head of global drug development and chief medical officer for Novartis, said during an interview with Xinhua. Benefitting from China’s pharmaceutical regulatory reform, which enables pharmaceutical companies to develop drugs much faster, Novartis has received 24 approvals for new drug applications in the country in the last two years, including nine new molecular entities, according to Tsai. One of the new drugs that will be available in the Chinese market is an orally taken asthma drug, which is described by Tsai as unique because most of the drugs for asthma are not taken orally. Tsai said the respiratory disease is one of the top five diseases in China. The company will report the results of a 5,000-patient study for the drug before the end of the year.